Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum [1] (multiple letters)

Journal of the American Academy of Dermatology

Volumn 42, Issue 2 I, 2000, Pages 304-305

  Richter Hintz, D ^a   Schuppe, H C ^a   Homey, B ^a   Lehmann, P ^a   Ruzicka, T ^a   Sauder, D N ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; TACROLIMUS;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; LETTER; PRIORITY JOURNAL; PYODERMA GANGRENOSUM;

EID: 0033930391     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(00)90149-X     Document Type: Letter

References (6)

1. HC Schuppe B Homey T Assmann R Martens T Ruzicka Topical tacrolimus for pyoderma gangrenosum Lancet 351 1998 832
2. T Ruzicka T Bieber E Schöpf A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group N Engl J Med 337 1997 816 821
3. B Homey A Assmann HW Vohr P Ulrich AI Lauerma T Ruzicka Topical FK506 suppresses cytokine and costimulatory molecule in epidermal and local draining lymph node cells during primary skin immune responses J Immunol 160 1998 5331 5340
4. G Michel L Kemeny B Homey T Ruzicka FK506 in the treatment of inflammatory skin disease: promises and perspectives Immunol Today 17 1996 106 108
5. B Homey HC Schuppe T Assmann A local lymph node assay to analyse immunosuppressive effects of topically applied drugs Eur J Pharmacol 325 1997 199 207
6. S Reitamo J Rissanen A Remitz H Granlund P Erkko P Elg Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial J Invest Dermatol 111 1998 396 398